Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12070
Title: Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases.
Authors: Yeo, Dannel;Huynh, Nhi;Beutler, John A;Christophi, Christopher;Shulkes, Arthur;Baldwin, Graham S;Nikfarjam, Mehrdad;He, Hong
Affiliation: Molecular Targets Laboratory, National Cancer Institute, Frederick, MD 21702, United States.
Department of Surgery, University of Melbourne, Austin Health, Melbourne, Victoria 3084, Australia.
Department of Surgery, University of Melbourne, Austin Health, Melbourne, Victoria 3084, Australia. Electronic address: hong.he@unimelb.edu.au.
Issue Date: 31-Jan-2014
Citation: Cancer Letters 2014; 346(2): 264-72
Abstract: Pancreatic cancer is one of the most lethal of human malignancies. Nearly 100% cases of pancreatic cancer carry mutations in KRas. P-21-activated kinases (PAKs) are activated by and act downstream of KRas. Glaucarubinone, a natural product first isolated from the seeds of the tree Simarouba glauca, was originally developed as an antimalarial drug, and has more recently been recognised as an anticancer agent. The aims of this study were to determine whether glaucarubinone, alone or in combination with the front-line chemotherapeutic agent gemcitabine, would inhibit the growth of pancreatic cancer cells in vitro or in vivo and the mechanism involved. Growth of the human pancreatic cancer cell lines PANC-1 and MiaPaCa-2 was measured by (3)H-thymidine incorporation in vitro, and by volume as xenografts in SCID mice. The expression and activities of the two serine/threonine kinases PAK1 and PAK4, which are key regulators of cancer progression, were measured by Western blotting. Here we report that glaucarubinone decreased proliferation and migration of pancreatic cancer cells in vitro, and reduced their growth as xenografts in vivo. Treatment with glaucarubinone and gemcitabine reduced proliferation in vitro and tumor growth in vivo more than treatment with either glaucarubinone or gemcitabine alone. Treatment with glaucarubinone reduced PAK1 and PAK4 activities, which were further decreased by the combination of glaucarubinone and gemcitabine. These results indicate that glaucarubinone reduced pancreatic cancer cell growth at least in part via inhibition of pathways involving PAK1 and PAK4. The synergistic inhibition by glaucarubinone and gemcitabine observed both in vitro and in vivo suggests that glaucarubinone may be a useful adjunct to current regimes of chemotherapy.
Internal ID Number: 24491405
URI: http://ahro.austin.org.au/austinjspui/handle/1/12070
DOI: 10.1016/j.canlet.2014.01.001
URL: http://www.ncbi.nlm.nih.gov/pubmed/24491405
Type: Journal Article
Subjects: Gemcitabine
Glaucarubinone
P21-activated kinases
Pancreatic cancer
Animals
Antineoplastic Combined Chemotherapy Protocols.pharmacology
Cell Growth Processes.drug effects
Cell Line, Tumor
Cell Movement.drug effects
Cyclin-Dependent Kinase Inhibitor p21.metabolism
Deoxycytidine.administration & dosage.analogs & derivatives.pharmacology
Down-Regulation.drug effects
Drug Synergism
Enzyme Activation
Glaucarubin.administration & dosage.analogs & derivatives.pharmacology
Humans
Mice
Mice, Nude
Pancreatic Neoplasms.drug therapy.enzymology.metabolism.pathology
Xenograft Model Antitumor Assays
p21-Activated Kinases.metabolism
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.